NCT02788006View on ClinicalTrials.gov

Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

September 30, 2017

Conditions
Colorectal Adenocarcinoma
Interventions
DRUG

Regorafenib 160 mg

Trial Locations (16)

Unknown

CH Victor Dupouy, Argenteuil

Centre François Bacless, Caen

Centre Oncologie et Radiothérapie, Dijon

Clinique du Cap d'Or, La Seyne-sur-Mer

Caluire et Cuire - Infirmerie Protestante de Lyon, Lyon

CH Lyon Sud (HCL) - Pierre Benite, Lyon

Hôpital privé Jean Mermoz, Lyon

Hôpital Européen, Marseille

CHRU - Hôpital Saint Eloi, Montpellier

CHR - Service HGE, Orléans

Saint Joseph, Paris

CH, Perpignan

Hôpital Haut Leveque, Pessac

CH Annecy Genevois, Pringy

Centre Paul Strauss, Strasbourg

Hôpital privé, Villeneuve-d'Ascq

All Listed Sponsors
lead

Federation Francophone de Cancerologie Digestive

OTHER

NCT02788006 - Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . | Biotech Hunter | Biotech Hunter